With this aim, we recently reported the targeting of a unique CD43-associated glycol-epitope (UMG1) with a novel CD3ε-BTCE, as a safe and highly selective strategy against T-ALL [12]. The gene discussed is SPN; the disease is acute lymphoblastic leukemia.